Feliciano Barrón

Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor–Mutated Lung Adenocarcinoma

Óscar Arrieta, Feliciano Barrón, M. Salinas Padilla et al. · JAMA Oncology · 2019 · 184 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer

Óscar Arrieta, Feliciano Barrón, Zyanya Lucía Zatarain-Barrón et al. · JAMA Oncology · 2020 · 153 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial

Jenny G. Turcott, María del Rocío Guillen Núñez, Diana Flores‐Estrada et al. · Supportive Care in Cancer · 2018 · 116 citations

Medicine, Oncology, Pharmacology +13

Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer

Diego de Miguel‐Pérez, Alessandro Russo, Óscar Arrieta et al. · Journal of Experimental & Clinical Cancer Research · 2022 · 106 citations · Full text

Medicine, Immunology, Oncology +17

Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)

Alejandro Ruíz-Patiño, Óscar Arrieta, Andrés F. Cardona et al. · Thoracic Cancer · 2019 · 62 citations · Full text

Medicine, Immunology, Oncology +16